This is a Phase 1 study testing a new treatment called VG2025, alone and in combination with nivolumab (Opdivo), for people with advanced solid tumors. These are cancers that have spread or returned, or for which standard treatments haven't worked. The study aims to find the safest dose of VG2025 and understand its side effects. VG2025 is an immunotherapy, meaning it works by using your body's immune system to fight cancer. You could be eligible if you are 18 or older, have a good performance status (meaning you can perform daily activities), and have advanced solid tumors. The study is currently unclear on its recruitment status and plans to enroll 12 participants.

Study design

This is a Phase 1, open-label study, meaning both you and your doctors will know which treatment you are receiving. It uses a dose-escalation design to find the right dose.

What's involved

You would receive VG2025 as injections into your tumor on specific days, either alone or with nivolumab. The treatment schedule varies depending on whether you are in the monotherapy or combination arm.

Compensation

Not stated in the trial record.

Follow-up

The study will track side effects and the maximum tolerated dose for 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.